

## VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

**Zurich, 29<sup>th</sup> of December 2023:** VERAXA Biotech AG, a pioneering company in the development of superior antibody-based cancer therapies and a portfolio company of Xlife Sciences AG (SIX: XLS), is proud to announce the acquisition of Synimmune GmbH and its innovative Phase I antibody (FLYSYN) for the treatment of Acute Myeloid Leukemia (AML). This marks a major milestone in the company's history and with the expansion of VERAXA's cancer pipeline it is hope for patients battling AML - one of the most common types of acute leukemia in adults.

The FLYSYN antibody was acquired by VERAXA Biotech AG from Xlife Sciences AG portfolio company Synimmune GmbH via a share deal. The deal included an upfront payment as well as several milestones and will reach a total deal value of up to 32 million EUR. With this clinical asset, VERAXA strengthens its internal cancer pipeline of innovative antibodies and antibody-drug conjugates (ADCs).

AML, characterized by its prevalence in individuals over the age of 68 and accounting for approximately 1% of all cancer occurrences, has long presented a challenge in the medical community, particularly for those under 45 where it is less common. The successful *First-in-Man* multicenter clinical study of FLYSYN focused on patients with AML who had measurable residual disease (MRD). The introduction of FLYSYN, is a testament to VERAXA Biotech AG's commitment to advancing healthcare and providing innovative solutions for serious health conditions.

Oliver R. Baumann, CEO of Xlife Sciences AG comments: «*Securing the innovative Phase I antibody, FLYSYN, for Acute Myeloid Leukemia (AML) treatment marks a significant step forward. This milestone reflects our commitment to advancing healthcare and sets the stage for a promising future in reshaping AML treatment.*»

Dr. Christoph Antz, CEO of VERAXA Biotech AG, stated: «*With FLYSYN, we are one step closer to offering better, more effective treatments for those affected by Acute Myeloid Leukemia.*»

As we continue to navigate the complexities of AML treatment, VERAXA Biotech AG remains steadfast in its mission to transform the landscape of medical care. For more information about VERAXA Biotech AG and our work in AML treatment, please visit <https://www.veraxa.com>.

### Financial calendar

Annual Report 2023	23 April 2024
Annual Shareholders Meeting 2024	20 June 2024
Half-Year Report 2024	19 September 2024

### Contact

Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [dennis.fink@xlifesciences.ch](mailto:dennis.fink@xlifesciences.ch)  
Information related to VERAXA Biotech AG: Dr. Christoph Antz, [antz@veraxa.com](mailto:antz@veraxa.com)

### About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit <https://www.xlifesciences.ch/en/home>

### About VERAXA Biotech AG

VERAXA Biotech strives to become a leading key agent for superior antibody-based cancer therapeutics. The company is using transformative innovations to develop therapeutic programs that show superior efficacy and less side effects for cancer patients. The companies' core activities focus on the development of therapeutic programs based on new antibody formats that use a more specific mode of action to treat cancer patients. VERAXA Biotech AG originates from two spin-off companies of the European Molecular Biology Laboratory (EMBL), Europe's most renowned institute for life science research and instrument development. For more information, please visit [www.veraxa.com](http://www.veraxa.com).



**Disclaimer**

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.